title: Cost considerations in the management of cancer in the older patient.
abstract: Patients aged 65 years and older represent 12% of the US population yet account for approximately 56% of cancer cases and 69% of all cancer mortalities. The overall cost of cancer in 2005 was $209.9 billion--$74 billion for direct medical costs and $118.4 billion for indirect mortality costs. This paper considers the direct, indirect, and out-of-pocket expenditures incurred by cancer patients > or = 50 years of age. Several major empirical studies on supportive care for older patients and cancer-related costs were reviewed. Insurance coverage, hematologic malignancies, squamous cell carcinoma of the head and neck, and cancers of the breast, prostate, colorectum, and lung were evaluated. Major sources of direct medical expenditures covered by third-party insurers for patients aged 65 years and older include extended length of hospital stay, home health assistance following hospital discharge, adjuvant prescription medications, lower-risk treatment (for prostate cancer), and advent of new pharmaceuticals (for colorectal cancer). The mean total direct medical cost for breast cancer is $35,164, and the cumulative cost for prostate cancer is $42,570. Emerging targeted cancer drug costs range from $20,000 to $50,000 annually per patient. Additional clinical trials and cost-effective treatments are needed for older patients to ameliorate the disproportionate economic burden among older individuals with cancer. Additional research about cancer costs may also lead to reforms in cancer care reimbursement, and therefore provide access to affordable health care for older patients.
authors.affiliation: Division of Geriatrics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Division of Hematology/Oncology, Chicago, Illinois 60611, USA.
authors.forename: June M
authors.initials: JM
authors.lastname: McKoy
authors.forename: Karen A
authors.initials: KA
authors.lastname: Fitzner
authors.forename: Beatrice J
authors.initials: BJ
authors.lastname: Edwards
authors.forename: Motasem
authors.initials: M
authors.lastname: Alkhatib
authors.forename: Cara C
authors.initials: CC
authors.lastname: Tigue
authors.forename: Narissa J
authors.initials: NJ
authors.lastname: Nonzee
authors.forename: Carlos R
authors.initials: CR
authors.lastname: Bolden
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002986:Clinical Trials as Topic / Q000191:economics; D003365:Costs and Cost Analysis; D018588:Fee-for-Service Plans / Q000191:economics; D017048:Health Care Costs; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D019458:Insurance Coverage / Q000191:economics; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D009369:Neoplasms / Q000191:economics* / Q000473:pathology / Q000628:therapy*; D014481:United States